Myelogenous Leukemia, Chronic, Chronic Phase Terminated Phase 2 Trials for Imatinib (DB00619)

IndicationStatusPhase
DBCOND0029944 (Myelogenous Leukemia, Chronic, Chronic Phase)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00038649Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-CTreatment